Search results

Skip to results

Type

Status

Last updated

Showing 1 to 11 of 11 results for valsartan

  1. Sparsentan for treating primary IgA nephropathy [ID6308]

    In development [GID-TA11359] Expected publication date: 25 June 2025

    Technology appraisal guidance
    In development

  2. Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)

    Evidence-based recommendations on sacubitril valsartan (Entresto) for treating symptomatic chronic heart failure with reduced ejection fraction.

    Technology appraisal guidance
    Published
    27 April 2016
    View recommendations

    Sections for TA388

  3. Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)

    Evidence-based recommendations on dapagliflozin (Forxiga) for symptomatic chronic heart failure with reduced ejection fraction in adults.

    Technology appraisal guidance
    Published
    24 February 2021
    View recommendations

    Sections for TA679

  4. Chronic heart failure in adults: diagnosis and management (NG106)

    This guideline covers diagnosing and managing chronic heart failure in people aged 18 and over. It aims to improve diagnosis and treatment to increase the length and quality of life for people with heart failure.

    NICE guideline
    Published
    12 September 2018
    View recommendations

    Sections for NG106

  5. Targeted-release budesonide for treating primary IgA nephropathy (review of TA937) [ID6485]

    In development [GID-TA11662] Expected publication date: 17 December 2025

    Technology appraisal guidance
    In development

  6. Chronic heart failure in adults: diagnosis and management: draft guidance consultation

    We are listening to your views on this NICE guideline. Comments close 8 July 2025.

    NICE guideline
    In consultation

  7. Sacubitril valsartan for treating chronic heart failure with reduced ejection fraction in people under 18 years [TSID10350]

      Status ...

    Technology appraisal guidance
    Topic selection

  8. Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)

    Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic heart failure with reduced ejection fraction in adults.

    Technology appraisal guidance
    Published
    9 March 2022
    View recommendations

    Sections for TA773

  9. Chronic heart failure in adults (QS9)

    This quality standard covers assessing, diagnosing and managing chronic heart failure in adults (aged 18 and over). It describes high-quality care in priority areas for improvement. Statements cover adults with chronic heart failure with reduced ejection fraction and adults with chronic heart failure with preserved ejection fraction, unless otherwise stated.

    Quality standard
    Last updated
    10 January 2023
    View quality statements

    Sections for QS9

  10. Sacubitril valsartan for treating chronic heart failure with preserved ejection fraction [ID1606]

    Discontinued [GID-TA11257]

    Technology appraisal guidance
    Discontinued

  11. Hypertension in adults. Patient decision aid on how do I control my blood pressure? Lifestyle options and choice of medicines

    medicines commonly end in 'artan' (for example, candesartan, losartan and valsartan). CCB stands for 'calcium channel blocker'. The...